News | January 07, 2026
Merck completes acquisition of Cidara Therapeutics
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
Cidara will become a wholly owned subsidiary of Merck and the common stock of Cidara will no longer be listed or traded on the Nasdaq Global Market
The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices
The acquisition adds HLD-0915, a once-daily oral therapy for prostate cancer, to Johnson & Johnson’s nearly 20-year legacy of innovation in the disease
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
CIRRUS-HCM, an open-label, multi-part study, evaluates EDG-7500 in patients with obstructive and nonobstructive HCM
The funding will support the pivotal Phase 3 clinical trial of neridronate in CRPS-1
If approved, CUTX-101 will be the first and only FDA approved treatment available for Menkes disease
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
The companies aim to expand treatment options for millions living with metabolic disorders
Akero became a wholly owned subsidiary of Novo Nordisk
Subscribe To Our Newsletter & Stay Updated
